```json
{
  "treatment_information": [
    {
      "treatment_type": "medication",
      "specific_treatment": "omalizumab",
      "start_date": "1998-01-01",
      "end_date": "Not specified",
      "dosage_or_details": "Initially treated in a 32-week randomized, double-blind, placebo-controlled study; subsequent treatment during a 6-year extension phase.",
      "treatment_response": "Clinical improvement with absence of hospitalizations for severe attacks, disappearance of pollen-induced rhinitis, and improved respiratory function."
    },
    {
      "treatment_type": "medication",
      "specific_treatment": "fluticasone",
      "start_date": "Not specified",
      "end_date": "Not specified",
      "dosage_or_details": "Reduced to 500 µg/day for the twin who received omalizumab; the other required 1250 µg/day.",
      "treatment_response": "Reduced dosage for the twin on omalizumab; persistent exacerbations for the other twin."
    },
    {
      "treatment_type": "medication",
      "specific_treatment": "oral corticosteroids",
      "start_date": "Not specified",
      "end_date": "Not specified",
      "dosage_or_details": "Occasional administration for the twin treated with omalizumab.",
      "treatment_response": "Needed regular courses for the other twin due to persistent exacerbations."
    }
  ],
  "treatment_timeline": [
    {
      "date": "1998-01-01",
      "event": "Twins enrolled in a 32-week randomized, double-blind, placebo-controlled study."
    },
    {
      "date": "1998-01-01",
      "event": "One twin received omalizumab and the other a placebo."
    },
    {
      "date": "Not specified",
      "event": "Omalizumab treatment continued for both twins during a 6-year extension phase."
    }
  ]
}
```